AUA 2025: The First Report of Disease-Free Survival Analyses from the NIAGARA Trial of Perioperative Durvalumab plus Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
AUA 2025, bladder cancer, Muscle-Invasive Bladder Cancer (MIBC), Durvalumab, NIAGARA Trial, Disease-Free Survival Analyses from the NIAGARA Trial of Perioperative Durvalumab plus Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.